ARDX vs IRWD
ARDX: A commercial-stage biotech company leveraging its proprietary NHE3 inhibitor platform to treat gastrointestinal and cardiorenal conditions. IRWD: Ironwood Pharmaceuticals is a GI-focused biotech company commercializing the market-leading treatment for IBS-C and CIC, LINZESS, while advancing its late-stage pipeline asset for short bowel syndrome.
Side-by-side fundamentals
| Metric | ARDX | IRWD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.27 | $3.87 | |
| Market cap | $815M | $639M | |
| P/E as of 2026-10-08 | n/a | 6.62 | |
| Net margin FY2025, SEC XBRL | -15.1% | +8.1% | IRWD higher |
| Operating margin FY2025, SEC XBRL | -10.1% | +33.3% | IRWD higher |
| ROE FY2025, SEC XBRL | -36.9% | n/a | |
| ROA FY2025, SEC XBRL | -12.3% | +6.1% | IRWD higher |
| Debt / equity as of 2026-09-03 | 1.69 | 0.56 | IRWD lower |
| Revenue growth (YoY) as of 2026-09-03 | +16.8% | +13.8% | ARDX higher |
| Revenue CAGR (3y) SEC XBRL | +98.4% | -10.3% | ARDX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.71 | 1.20 | |
| 1-year return as of 2026-10-08 close | -35.4% | +144.9% | IRWD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.